263 related articles for article (PubMed ID: 35313761)
21. Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies.
Sadeghalvad M; Mansourabadi AH; Noori M; Nejadghaderi SA; Masoomikarimi M; Alimohammadi M; Rezaei N
Rev Med Virol; 2023 Jan; 33(1):e2359. PubMed ID: 35491495
[TBL] [Abstract][Full Text] [Related]
22. Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients.
Schietzel S; Anderegg M; Limacher A; Born A; Horn MP; Maurer B; Hirzel C; Sidler D; Moor MB
RMD Open; 2022 Feb; 8(1):. PubMed ID: 35115385
[TBL] [Abstract][Full Text] [Related]
23. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
24. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
[TBL] [Abstract][Full Text] [Related]
25. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.
Fendler A; de Vries EGE; GeurtsvanKessel CH; Haanen JB; Wörmann B; Turajlic S; von Lilienfeld-Toal M
Nat Rev Clin Oncol; 2022 Jun; 19(6):385-401. PubMed ID: 35277694
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
Lee ARYB; Wong SY; Chai LYA; Lee SC; Lee MX; Muthiah MD; Tay SH; Teo CB; Tan BKJ; Chan YH; Sundar R; Soon YY
BMJ; 2022 Mar; 376():e068632. PubMed ID: 35236664
[TBL] [Abstract][Full Text] [Related]
27. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
Masuda T; Murakami K; Sugiura K; Sakui S; Philip Schuring R; Mori M
Vaccine; 2022 Mar; 40(13):2044-2052. PubMed ID: 35177302
[TBL] [Abstract][Full Text] [Related]
28. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
Lozano-Rodríguez R; Valentín-Quiroga J; Avendaño-Ortiz J; Martín-Quirós A; Pascual-Iglesias A; Terrón-Arcos V; Montalbán-Hernández K; Casalvilla-Dueñas JC; Bergón-Gutiérrez M; Alcamí J; García-Pérez J; Cascajero A; García-Garrido MÁ; Balzo-Castillo ÁD; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; Benito JM; Rallón N; Vela-Olmo C; López-Morejón L; Cubillos-Zapata C; Aguirre LA; Fresno CD; López-Collazo E
Cell Rep; 2022 Jan; 38(2):110235. PubMed ID: 34986327
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews.
Tan TT; Ng HJ; Young B; Khan BA; Shetty V; Azmi N; Clissold S
Expert Rev Vaccines; 2023; 22(1):341-365. PubMed ID: 36920116
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.
Funakoshi Y; Yakushijin K; Ohji G; Hojo W; Sakai H; Takai R; Nose T; Ohata S; Nagatani Y; Koyama T; Kitao A; Nishimura M; Imamura Y; Kiyota N; Harada K; Tanaka Y; Mori Y; Minami H
J Infect Chemother; 2022 Apr; 28(4):516-520. PubMed ID: 35090826
[TBL] [Abstract][Full Text] [Related]
31. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients.
Longlune N; Nogier MB; Miedougé M; Gabilan C; Cartou C; Seigneuric B; Del Bello A; Marion O; Faguer S; Izopet J; Kamar N
Nephrol Dial Transplant; 2021 Aug; 36(9):1704-1709. PubMed ID: 34057463
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity, effectiveness, and safety of SARS-CoV-2 vaccination in people with HIV.
Griffin DWJ; Pai Mangalore R; Hoy JF; McMahon JH
AIDS; 2023 Jul; 37(9):1345-1360. PubMed ID: 37070539
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination.
König M; Torgauten HM; Tran TT; Holmøy T; Vaage JT; Lund-Johansen F; Nygaard GO
JAMA Neurol; 2022 Mar; 79(3):307-309. PubMed ID: 35072702
[TBL] [Abstract][Full Text] [Related]
34. Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients.
Easdale S; Shea R; Ellis L; Bazin J; Davis K; Dallas F; Thistlethwayte E; Ethell M; Potter M; Arias C; Anthias C; Nicholson E
Transplant Cell Ther; 2021 Oct; 27(10):880.e1-880.e4. PubMed ID: 34293520
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review.
Piechotta V; Mellinghoff SC; Hirsch C; Brinkmann A; Iannizzi C; Kreuzberger N; Adams A; Monsef I; Stemler J; Cornely OA; Bröckelmann PJ; Skoetz N
Blood Cancer J; 2022 May; 12(5):86. PubMed ID: 35641489
[TBL] [Abstract][Full Text] [Related]
36. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
38. A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques.
O'Connor MA; Erasmus JH; Randall S; Archer J; Lewis TB; Brown B; Fredericks M; Groenier S; Iwayama N; Ahrens C; Garrison W; Wangari S; Guerriero KA; Fuller DH
Front Immunol; 2021; 12():800723. PubMed ID: 34992610
[TBL] [Abstract][Full Text] [Related]
39. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
40. Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis.
Yin J; Chen Y; Li Y; Zhang X; Wang C
Hum Vaccin Immunother; 2022 Nov; 18(6):2119763. PubMed ID: 36161976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
